Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Lombroso, , Benedetto,
DOB: 07-MAY-1989 (Age: 36)
Gender: male
Address:
Stretto Zaccagnini, 924
37121 Verona (Italy)
ID: 9244-804304-9 (ECI)
Report
Date: 09-APR-2023
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Ospedale Civile Maggiore
Piazzale Aristide Stefani 1
37124 Verona (Italy)
Specimen
Collected: 09-APR-2023

Chemistry

Test 09-APR-2023 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.0 4 - 6 %
Glucose [Mass/volume] in Blood 72.4 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 14.5 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 1.4 H 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 10.1 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 137.5 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.2 3.5 - 5.2 mmol/L
Chloride [Moles/volume] in Blood 102.6 98 - 114 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 20.7 L 24 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 144.9 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 129.1 40 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 94.4 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 24.7 L 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The results show mildly elevated creatinine, low total CO₂, and low HDL cholesterol. HbA1c is at the upper limit of normal, suggesting possible early glucose metabolism changes. Other parameters are within normal limits. Recommend clinical correlation for possible early renal impairment, metabolic acidosis, and increased cardiovascular risk due to low HDL. Follow-up and further evaluation are advised.